A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.
Chemotherapy drugs cisplatin and gemcitabine are typically given to people with cancer cells that line the urethra, bladder, ureters and renal pelvis. Yet, cisplatin-based therapies do not cure these patients, and attempts to combine with novel therapies have failed to extend survival.